Aboleris Holdco SA
Aboleris Holdco reported total assets of €14.8m at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Jun 2026).
The score of Aboleris Holdco shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Equity +15 % Total assets +13 %
Accounts of the company itself (not consolidated).
The full file covers 3 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Aboleris Holdco's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Jun 2026
- Year ended 31 Dec 2024filed on 06 May 2025
- Year ended 31 Dec 2023filed on 28 Mar 2024
Aboleris Holdco's financial analysis
- Solvency96.6%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Aboleris Holdco
Aboleris Holdco's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0803.217.012
- VAT number
- BE0803217012
- Peppol
- Registered · 0208:0803217012 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 27 Jun 2023
- Registered office
- 6041 Charleroi
- Latest accounts
- 2025 · filed on 19 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Aboleris Holdco (SA) has been based in Charleroi since 2023, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €5.81m and equity of €14.3m; its revenue is not published. Its solvency stands at 96.6%, above the median of its sector (57.9%).
Companies similar to Aboleris Holdco
Companies in the same business, of comparable size and area, outside its group.
- ConvEyXo Research and experimental development on natural sciences and engineering Charleroi · balance sheet €10.3m
- EXO Biologics Research and experimental development on natural sciences and engineering Liège · balance sheet €11.7m
- OSIVAX Belgique Research and experimental development on natural sciences and engineering Liège · balance sheet €17.0m
- Biotalys Research and experimental development on natural sciences and engineering Ghent · balance sheet €16.3m
- The Akkermansia Company Research and experimental development on natural sciences and engineering Mont-Saint-Guibert · balance sheet €16.9m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- Nanocyl Research and experimental development on natural sciences and engineering Sambreville · balance sheet €13.2m
- Aquilon Pharmaceuticals Research and experimental development on natural sciences and engineering Seraing · balance sheet €11.1m
Frequently asked questions about Aboleris Holdco
What is the revenue of Aboleris Holdco?
Aboleris Holdco files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Aboleris Holdco?
In Belgium, the VAT number is the company number prefixed with BE: BE0803217012 for Aboleris Holdco, if the company is VAT-registered. Its company number (CBE) is 0803.217.012.
Where is the registered office of Aboleris Holdco?
According to the CBE register, the registered office of Aboleris Holdco is in 6041 Charleroi.
What is the equity of Aboleris Holdco?
At the close of the 2025 financial year, the equity of Aboleris Holdco amounts to 14,292,930 €, a solvency of 96.6% of total assets.
Who manages Aboleris Holdco?
The register lists 12 active mandates at Aboleris Holdco. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Aboleris Holdco
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →